Thomas Sleweon, MD
Infectious Disease · Highland, INNPI 1114909769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 264 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,544, 2.1 times the $740 reported in 2019. Among infectious disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- AbbVie$979
- Merck$616
- Paratek Pharmaceuticals, Inc.$606
- Melinta Therapeutics, LLC$480
- Gilead$354
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$611%
- Food & beverage$6,23896%
- Education$1773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 45 | $1,313 |
| AbbVie(2 entities) | 32 | $979 |
| Merck | 34 | $616 |
| Paratek Pharmaceuticals, Inc. | 24 | $606 |
| Melinta Therapeutics, LLC | 11 | $480 |
| Gilead | 12 | $354 |
| Shionogi Inc | 14 | $333 |
| Ferring Pharmaceuticals Inc. | 8 | $262 |
| Cumberland Pharmaceuticals, Inc. | 5 | $233 |
| Napo Pharmaceuticals Inc | 13 | $220 |
| Smith+Nephew | 24 | $219 |
| La Jolla Pharmaceutical Company | 5 | $141 |
| Theratechnologies Inc. | 6 | $139 |
| Insmed, Inc. | 4 | $125 |
| Johnson & Johnson | 7 | $101 |
| Vyera Pharmaceuticals, LLC | 4 | $71 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Mayne Pharma Commercial LLC | 3 | $42 |
| EMD Serono, Inc. | 2 | $38 |
| Philips North America LLC | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $26 |
| Octapharma USA, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $19 |
| Romark Laboratories, LC | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,475 in reported general payments places this provider in the 90th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 13 | $52,897 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $44,071 |
| Daptomycin | 16 | $40,971 |
| Cefepime Hcl | 39 | $5,795 |
| Vancomycin Hcl | 18 | $2,943 |
| Doxycycline Monohydrate | 19 | $627 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $195 |
| CefuroximeCefuroxime Axetil | 13 | $180 |
| Ciprofloxacin Hcl | 22 | $135 |
| Metronidazole | 12 | $131 |
| Cephalexin | 17 | $77 |
| Levofloxacin | 21 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Triumeq | $1,313 | $96,96825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Highland
- Ralph VillaranHighland$2K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
- Darron BrownIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.